Skip to main content
SpringerLink
Log in

The Croatian government is to pay for early-stage human epidermal growth factor receptor 2-positive breast cancer patients to receive Roche's Herceptin

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Croatia to pay for early-stage Herceptin. Scrip: 8, No. 3246, 30 Mar 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The Croatian government is to pay for early-stage human epidermal growth factor receptor 2-positive breast cancer patients to receive Roche's Herceptin. Pharmacoecon. Outcomes News 526, 11 (2007). https://doi.org/10.2165/00151234-200705260-00025

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705260-00025

Keywords

Search

Navigation